3192 results for «988»
3192 results
Introducing the next era of coronary intravascular lithotripsy: an aero-volution in calcium modification
27 Feb 2026 – From Euro4C Annual Meeting
Explore the next era of coronary intravascular lithotripsy featuring innovative technology for calcium modification. This session covers the unique mechanism of action, practical application in complex cases, and recent clinical evidence supporting its safety and efficacy.
Hot topics and evidence on structural interventions in 2025 and 2026
14 Feb 2026 – From PCR Tokyo Valves 2026
Delve into the emerging clinical evidence and key hot topics shaping transcatheter interventions for aortic, mitral, and tricuspid valve diseases anticipated to influence clinical practice in 2025 and 2026. This session reviews stroke prevention, valve interventions across the three valves, and integrates recent and upcoming data...
Novel Hertz Contact intravascular lithotripsy: calcium fragmentation with zero trade-offs
27 Feb 2026 – From Euro4C Annual Meeting
This session introduces the novel Hertz Contact intravascular lithotripsy system, designed for effective calcium fragmentation without trade-offs. It covers lesion types amenable to treatment, system mechanism, optimization tips, and discusses real-world cases along with supporting clinical trial evidence.
Prevention and management of TAVI complications
14 Feb 2026 – From PCR Tokyo Valves 2026
This session addresses the prevention and management of major complications associated with transcatheter aortic valve implantation (TAVI). Attendees will gain a detailed understanding of mechanisms behind cerebral infarction, haemolysis, valve infolding, pacemaker implantation, and valve migration, along with expert strategies for recognition, decision-making, and bailout techniques...
Primary mitral TEER in small anatomy - LIVE case
15 Feb 2026 – From PCR Tokyo Valves 2026
An 89-year-old male with diabetes mellitus, hypertension, chronic kidney disease (eGFR: 46), and CAD with a history of NSTEMI and CTO of the RCA, presented with symptomatic primary mitral regurgitation (P1–P2 prolapse) and preserved LV function (56%).
One Pascal ACE device was implanted.
LIVE Educational Case from Nagoya...
Guidelines update
15 Feb 2026 – From PCR Tokyo Valves 2026
This session reviews the latest updates in the ESC/EACTS guidelines for structural heart disease, emphasizing their clinical implications and future trends. Participants will gain understanding of changes in aortic, mitral, and tricuspid valve recommendations, including new age cutoffs, asymptomatic disease management, and the evolving role of...
Future devices and techniques for structural heart disease
15 Feb 2026 – From PCR Tokyo Valves 2026
This session surveys the future landscape of structural heart disease treatment, addressing current limitations in transcatheter valve technologies and presenting emerging devices and techniques for aortic, mitral, and tricuspid valves. Attendees will gain insights into innovations poised to transform therapeutic options for structural heart disease.
Outcomes in patients with atrial fibrillation randomized to receive LAA closure or oral anticoagulation: Primary results of the CHAMPION-AF clinical trial
28 Mar 2026
During the first Late-Breaking Trial session of the 2026 ACC Congress held in New Orleans, Saibal Kar, principal investigator of the CHAMPION-AF trial, presented the 3-year results of this groundbreaking study, which were simultaneously published in the NEJM (DOI: 10.1056/NEJMoa2517213).
Author
RIVER: Rivaroxaban for valvular heart disease and atrial fibrillation
05 Sep 2023
Alex Sticchi provides his take on the results of the RIVER trial, which were presented by Pedro Gabriel Barros E Silva during the ESC 2023 congress in Amsterdam.
Rivaroxaban versus Warfarin in Patients with Bioprosthetic Valves According to Valvular Heart Disease Etiology, and Thrombotic and Bleeding Risks: Insights from...
Author
TRILUMINATE pivotal: A landmark randomized clinical trial of transcatheter tricuspid valve edge-to-edge repair for tricuspid regurgitation
04 Mar 2023
Jonathan Curio and Alex Sticchi provide their take on this clinical trial which was presented by Paul Sorajja at the American College of Cardiology Scientific Session (ACC.23/WCC).
Author
Author
The JenaValve Trilogy™ heart valve system in high surgical risk patients with symptomatic, severe aortic regurgitation: The ALIGN AR Trial
25 Oct 2023
Nicola Ryan provides her take on the ALIGN AR trial which was presented by Vinod H. Thourani at TCT Congress 2023. The Align AR trial is a prospective single-arm investigation device exemption study assessing the safety and efficacy of the Trilogy transcatheter heart valve system in patients with...
Author
TRI.fr trial - Multicentric randomised evaluation of the transcatheter edge-to-edge repair in the treatment of severe isolated secondary tricuspid regurgitation
31 Aug 2024
Alex Sticchi provides his take on the results of the TRI.FR trial presented by Erwan Donal at the ESC Congress 2024 in London.
Author
